MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.cardfail.2021.06.010

Медицинская библиотека · Journal of cardiac failure · 2021

Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent.

Griffin Jan M, Chasler Jessica, Wand Alison L, Okada David R, Smith J Nikolhaus, Saad Elie, Tandri Hari, Chrispin Jonathan, Sharp Michelle, Kasper Edward K, Chen Edward S, Gilotra Nisha A

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Cardiac sarcoidosis (CS) is a major cause of morbidity and mortality in patients with systemic sarcoidosis. Steroid-sparing agents are increasingly used, despite a lack of randomized trials or published guidelines to direct treatment.

METHODS AND

RESULTS

This retrospective study included 77 patients with CS treated with prednisone monotherapy (n = 32) or a combination with mycophenolate mofetil (n = 45) between 2003 and 2018. Baseline characteristics and clinical outcomes were evaluated. The mean patient age was 53 ± 11 years at CS diagnosis, 66.2% were male, and 35.1% were Black. The total exposure to maximum prednisone dose (initial prednisone dose × days at dose) was lower in the combination therapy group (1440 mg [interquartile range (IQR), 1200-2760 mg] vs 2710 mg [IQR, 1200-5080 mg]; P = .06). On 18F-fluorodeoxyglucose positron emission tomography scans, both groups demonstrated a significant decrease in the cardiac maximum standardized uptake value after treatment: a median decrease of 3.9 (IQR 2.7-9.0, P = .002) and 2.9 (IQR 0-5.0, P = .001) for prednisone monotherapy and combination therapy, respectively. Most patients experienced improvement or complete resolution in qualitative cardiac 18F-fluorodeoxyglucose uptake (92.3% and 70.4% for the prednisone and combination therapy groups, respectively). Mycophenolate mofetil was well tolerated.

CONCLUSIONS

Mycophenolate mofetil in combination with prednisone for the treatment of CS may minimize corticosteroid exposure and decrease cardiac inflammation without significant adverse effects.

Для цитирования: Griffin Jan M, Chasler Jessica, Wand Alison L, Okada David R, Smith J Nikolhaus, Saad Elie, Tandri Hari, Chrispin Jonathan, Sharp Michelle, Kasper Edward K, Chen Edward S, Gilotra Nisha A. Management of Cardiac Sarcoidosis Using Mycophenolate Mofetil as a Steroid-Sparing Agent.. Journal of cardiac failure. 2021. DOI: 10.1016/j.cardfail.2021.06.010.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.